0001209191-23-037091.txt : 20230614 0001209191-23-037091.hdr.sgml : 20230614 20230614170649 ACCESSION NUMBER: 0001209191-23-037091 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230614 FILED AS OF DATE: 20230614 DATE AS OF CHANGE: 20230614 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Duncan Barbara Gayle CENTRAL INDEX KEY: 0001353128 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39344 FILM NUMBER: 231014941 MAIL ADDRESS: STREET 1: C/O INTERCEPT PHARMACEUTICALS, INC. STREET 2: 18 DESBROSSES STREET CITY: NEW YORK STATE: NY ZIP: 10013 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Fusion Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001805890 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 270 LONGWOOD ROAD SOUTH CITY: HAMILTON STATE: A6 ZIP: L8P 0A6 BUSINESS PHONE: 289-799-0891 MAIL ADDRESS: STREET 1: 270 LONGWOOD ROAD SOUTH CITY: HAMILTON STATE: A6 ZIP: L8P 0A6 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-14 0 0001805890 Fusion Pharmaceuticals Inc. FUSN 0001353128 Duncan Barbara Gayle C/O FUSION PHARMACEUTICALS, INC. 2 INTERNATIONAL PLACE, SUITE 2310 BOSTON MA 02110 1 0 0 0 0 Stock Opion (Right to Buy) 4.64 2023-06-14 4 A 0 17000 0.00 A 2033-06-13 Common Stock 17000 17000 D This option fully vests on the earlier of (i) June 14, 2024 or (ii) the 2024 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc. /s/Maria Stahl as Attorney-in-Fact for Barbara Duncan 2023-06-14